Bridgebio pharma, inc. (BBIO) 2025Q4 shows flat or mildly positive contract liabilities growth (0 ~ 15%). This indicates a stable performance in order intake, providing a solid base for future revenue. The company’s operations remain healthy, and this status fits well with investors preferring low volatility and steady development.